immune-stimulatory

Ginsenoside Rg4 is a natural product

Notoginsenoside R1 (Sanchinoside R1) has been shown to exhibit antioxidant, antiapoptotic, anti-inflammatory, and immune-stimulatory properties.

MG-C-30 is an orally active CD27 agonist with an EC50 of 0.84 μM. It activates co-stimulatory signaling in NK cells and T cells, thereby enhancing the immune response. In the EG7-OVA mouse model, MG-C-30 demonstrates antitumor activity.

TMX-201, a TLR7 ligand-phospholipid conjugate, exhibits potent immune-stimulatory activity and is utilized in breast cancer and melanoma research [1].

Rocatinlimab represents a highly specialized humanized IgG1 monoclonal antibody specifically engineered to target the OX40 receptor (CD134) with exceptional binding affinity. It effectively facilitates the measurable blockade of the OX40-OX40L co-stimulatory axis while simultaneously inducing the targeted depletion of OX40-positive activated T cells through antibody-dependent cellular cytotoxicity (ADCC) across various preclinical experimental models to evaluate the restoration of immune homeostasis during strictly monitored laboratory observation periods.

ATAC21 is a linker-immune-stimulatory compound created by conjugating a noncleavable maleimide-PEG4 linker, which includes a succinimide group, with an immune-stimulatory agent. This compound can be further conjugated with SBT-040 (anti-CD40 antibody) to form a conjugate [1].

Anti-CD48 Antibody is a humanized monoclonal antibody targeting CD48 (SLAMF2/BLAST-1). CD48 is a GPI-anchored cell surface glycoprotein belonging to the Signaling Lymphocyte Activation Molecule (SLAM) family, widely expressed on lymphocytes, monocytes, and endothelial cells. It serves as a high-affinity ligand for the NK cell receptor 2B4 (CD244) and the T cell receptor CD2, playing a role in mediating immune cell adhesion, activation, and co-stimulatory signaling. Research indicates that CD48 is highly expressed on the surface of hematologic malignancies such as multiple myeloma (MM). By specifically binding to CD48, Anti-CD48 Antibody not only blocks its interaction with ligands but also induces potent Antibody-Dependent Cellular Cytotoxicity (ADCC) and Complement-Dependent Cytotoxicity (CDC), leading to direct tumor cell killing. It is a significant candidate tool for researching immunotherapy in hematological cancers.

BMS-986178 is a fully human OX40 (CD134) agonistic monoclonal antibody. By binding to the OX40 receptor on activated T cells, it provides essential co-stimulatory signals that enhance T cell expansion, survival, and cytokine secretion, thereby achieving anti-tumor effects in various solid tumor studies by recruiting effector immune cells.

Anti-TNFRSF5/CD40 Antibody is a highly specialized monoclonal antibody target the human tumor necrosis factor receptor superfamily member 5, which is also widely known as CD40, modulation of co-stimulatory signaling pathways and immune cell activation across various preclinical experimental models to regulate humoral immunity and dendritic cell maturation.

NTX-1088 is a humanised monoclonal antibody targeting PVR/CD155, which blocks the interaction between PVR and the co-stimulatory receptor DNAM1/CD226. It induces DNAM1 recovery and immune activation, making it suitable for anti-tumour immunotherapy.

Ciltistotug is a monoclonal antibody that targets human CD40 (TNFRSF5). By binding to CD40, it activates immune cells and exhibits immune-stimulatory and anti-tumor activities. Ciltistotug holds potential for research in cancer immunotherapy.

Soyasaponin Ab (Standard) is a reference standard for research and analysis in studies involving Soyasaponin Ab. Soyasaponin Ab may represent a viable candidate for effective vaccine adjuvant, TLR4 receptor dependent pathway may be involved in immune stimulatory effects of soyasaponin Ab.

Ginsenoside Rg4 (Standard) is a reference standard for research and analysis in studies involving Ginsenoside Rg4. Ginsenoside Rg4 is isolated from the leaves of Panax ginseng C. A. Meyer. Ginsenoside Rg4 is a protopanaxatriol type ginsenoside with anti-septic, anti-diabetic, wound healing, immune-stimulatory, and anti-antioxidant properties.

Soyasaponin Ab may represent a viable candidate for effective vaccine adjuvant, TLR4 receptor dependent pathway may be involved in immune stimulatory effects of soyasaponin Ab.